Searched for: in-biosketch:yes
person:charvl01
A central hub model for remote delivery of multisite clinical trial interventions
Charvet, Leigh; Pilloni, Giuseppina; Becker, Jacqueline H; Wisnivesky, Juan; Federman, Alex D; Pehel, Shayna; Ko, Timothy S; Koltai, Deborah C; Knopman, David S; Laskowitz, Daniel T; O'Steen, Ashley; James, Melissa; Cox, Wendy; Karwowski, Jeannie; Zimmerman, Kanecia O
Digital health technologies enable remote delivery of clinical interventions, creating opportunities to redesign multisite trials. Traditional trials require participating sites to deliver interventions independently, potentially increasing implementation variability and operational complexity. Centralized models instead allow local recruitment and assessments while coordinating intervention delivery through one hub. We describe the feasibility of this model in RECOVER-NEURO, an NIH-funded, five-arm phase 2 randomized trial overseen by the Duke Clinical Research Institute. The trial enrolled 328 participants across 22 US sites with cognitive symptoms associated with long COVID. Sites conducted recruitment, consent, and clinical assessments, while an NYU Langone Health hub managed study kit preparation and distribution, device programming, onboarding, remote supervision, adherence monitoring, and equipment recovery. Participants were randomized to BrainHQ cognitive training alone; BrainHQ plus cognitive rehabilitation (PASC-CoRE), delivered via telehealth by Mount Sinai and Emory University investigators; BrainHQ plus active transcranial direct current stimulation (tDCS); BrainHQ plus sham tDCS; or non-adaptive computer-based puzzles and games as an active comparator. Interventions were delivered remotely over 10 weeks using home-based study kits. Participants completed a mean of 44.0 ± 10.9 sessions over 68.8 ± 11.3 days. Of 320 participants who received intervention, 260 (81.3%) were consistently adherent. The hub initiated intervention within 13.5 ± 6.1 days of first participant contact, supported up to 168 concurrently active participants, and achieved a 96.9% equipment return rate. The intervention phase was completed in 375 days. These findings demonstrate the feasibility of centralized remote delivery of digital and device-based interventions in a large multisite trial and may inform future decentralized or hybrid clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT05965739.
PMCID:13754145
PMID: 43013534
ISSN: 2767-3170
CID: 6075824
A central hub model for remote delivery of multisite clinical trial interventions
Charvet, Leigh; Pilloni, Giuseppina; Becker, Jacqueline H; Wisnivesky, Juan; Federman, Alex D; Pehel, Shayna; Ko, Timothy S; Koltai, Deborah C; Knopman, David S; Laskowitz, Daniel T; O'Steen, Ashley; James, Melissa; Cox, Wendy; Karwowski, Jeannie; Zimmerman, Kanecia O
Digital health technologies enable remote delivery of clinical interventions, creating opportunities to redesign multisite trials. Traditional trials require participating sites to deliver interventions independently, potentially increasing implementation variability and operational complexity. Centralized models instead allow local recruitment and assessments while coordinating intervention delivery through one hub. We describe the feasibility of this model in RECOVER-NEURO, an NIH-funded, five-arm phase 2 randomized trial overseen by the Duke Clinical Research Institute. The trial enrolled 328 participants across 22 US sites with cognitive symptoms associated with long COVID. Sites conducted recruitment, consent, and clinical assessments, while an NYU Langone Health hub managed study kit preparation and distribution, device programming, onboarding, remote supervision, adherence monitoring, and equipment recovery. Participants were randomized to BrainHQ cognitive training alone; BrainHQ plus cognitive rehabilitation (PASC-CoRE), delivered via telehealth by Mount Sinai and Emory University investigators; BrainHQ plus active transcranial direct current stimulation (tDCS); BrainHQ plus sham tDCS; or non-adaptive computer-based puzzles and games as an active comparator. Interventions were delivered remotely over 10 weeks using home-based study kits. Participants completed a mean of 44.0 ± 10.9 sessions over 68.8 ± 11.3 days. Of 320 participants who received intervention, 260 (81.3%) were consistently adherent. The hub initiated intervention within 13.5 ± 6.1 days of first participant contact, supported up to 168 concurrently active participants, and achieved a 96.9% equipment return rate. The intervention phase was completed in 375 days. These findings demonstrate the feasibility of centralized remote delivery of digital and device-based interventions in a large multisite trial and may inform future decentralized or hybrid clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT05965739.
PMCID:13754145
PMID: 43013534
ISSN: 2767-3170
CID: 6075822
A central hub model for remote delivery of multisite clinical trial interventions
Charvet, Leigh; Pilloni, Giuseppina; Becker, Jacqueline H; Wisnivesky, Juan; Federman, Alex D; Pehel, Shayna; Ko, Timothy S; Koltai, Deborah C; Knopman, David S; Laskowitz, Daniel T; O'Steen, Ashley; James, Melissa; Cox, Wendy; Karwowski, Jeannie; Zimmerman, Kanecia O
Digital health technologies enable remote delivery of clinical interventions, creating opportunities to redesign multisite trials. Traditional trials require participating sites to deliver interventions independently, potentially increasing implementation variability and operational complexity. Centralized models instead allow local recruitment and assessments while coordinating intervention delivery through one hub. We describe the feasibility of this model in RECOVER-NEURO, an NIH-funded, five-arm phase 2 randomized trial overseen by the Duke Clinical Research Institute. The trial enrolled 328 participants across 22 US sites with cognitive symptoms associated with long COVID. Sites conducted recruitment, consent, and clinical assessments, while an NYU Langone Health hub managed study kit preparation and distribution, device programming, onboarding, remote supervision, adherence monitoring, and equipment recovery. Participants were randomized to BrainHQ cognitive training alone; BrainHQ plus cognitive rehabilitation (PASC-CoRE), delivered via telehealth by Mount Sinai and Emory University investigators; BrainHQ plus active transcranial direct current stimulation (tDCS); BrainHQ plus sham tDCS; or non-adaptive computer-based puzzles and games as an active comparator. Interventions were delivered remotely over 10 weeks using home-based study kits. Participants completed a mean of 44.0 ± 10.9 sessions over 68.8 ± 11.3 days. Of 320 participants who received intervention, 260 (81.3%) were consistently adherent. The hub initiated intervention within 13.5 ± 6.1 days of first participant contact, supported up to 168 concurrently active participants, and achieved a 96.9% equipment return rate. The intervention phase was completed in 375 days. These findings demonstrate the feasibility of centralized remote delivery of digital and device-based interventions in a large multisite trial and may inform future decentralized or hybrid clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT05965739.
PMCID:13754145
PMID: 43013534
ISSN: 2767-3170
CID: 6075823
Home-Based Transcranial Direct Current Stimulation for Depression: From Feasibility to Clinical Implementation
Pilloni, Giuseppina; Brunoni, Andre R; Charvet, Leigh
Home-based transcranial direct current stimulation (tDCS) for major depressive disorder (MDD) has progressed from early feasibility studies to an approved clinical treatment, highlighted by the US Food and Drug Administration's 2025 premarket approval of the Flow FL-100 device. This milestone shifts the field from asking whether home-based tDCS can be delivered safely and effectively to defining how it should be implemented in routine clinical practice. This review synthesizes the current evidence on treatment outcomes, adherence, and safety, with an emphasis on factors that determine successful real-world implementation. Randomized controlled trials support the efficacy of home-based tDCS when delivered using adequate cumulative dosing, structured treatment protocols, and appropriate supervision or adherence monitoring. In contrast, shorter-duration and fully unsupervised protocols have generally shown less favorable outcomes, although the independent contributions of dose, treatment duration, and supervision remain difficult to disentangle. High adherence has been reported with user-centered device design, standardized training, remote monitoring, and scalable supervision models that maintain treatment fidelity while supporting broad clinical deployment. Home-based tDCS has demonstrated an excellent safety profile when delivered using standardized equipment, structured protocols, and active monitoring, exemplified by more than 30,000 supervised home-based sessions delivered through a large academic clinical program without reported skin lesions or serious adverse events attributable to tDCS. Remaining priorities include optimizing acute and maintenance dosing strategies, identifying predictors and biomarkers of response, defining the role of paired behavioral interventions, personalizing treatment for special populations - including perinatal patients, older adults, and adolescents - and integrating home-based tDCS within interventional psychiatry care pathways. The evidence supports a transition from proof-of-concept to clinical implementation, with future research focused on optimizing delivery, personalizing treatment, and expanding access to evidence-based neuromodulation for depression.
PMCID:13634324
PMID: 42830939
ISSN: 1176-6328
CID: 6073878
Fatigue relief through neuroimaging-informed neuromodulation: a Perspective from the Italian Society of Neuromodulation and Neurotechnologies
Tecchio, F; Paulon, L; Antal, A; Armonaite, K; Assenza, G; Ayache, S S; Balsi, M; Benelli, A; Bertoli, M; Bevacqua, G; Bikson, M; Bocci, T; Brichetto, G; Capone, F; Cecconi, F; Centonze, D; Chalah, M A; Charvet, L; Conti, L; Croce, P; Di Filippo, M; Di Iorio, R; Di Russo, F; Ferraina, S; Granata, G; Grasso, M G; Grifoni, J; Grignolio Corsini, A; Guidetti, M; Koch, G; Kuppuswamy, A; Inglese, M; L'Abbate, T; Lanzone, J; Madeo, G; Malosio, M L; Micera, A; Mirabella, M; Nasios, G; Nitsche, M A; Nuzzo, D; Oliviero, A; Parazzini, M; Pasqualetti, P; Pellegrino, G; Picone, P; Pitzalis, S; Pizzichino, A; Porcaro, C; Quartarone, A; Rossini, P M; Signorelli, P; Straudi, S; Tomassini,; Totaro, R; Ulivelli, M; Versace,; Wischnewski, M; Zappasodi, F; Rossi, S; Priori, A
PMID: 42762880
ISSN: 1873-7528
CID: 6072975
An examination of the influence of prefrontal cortical brain stimulation on sexual decision making
Shaw, Michael T; Cingranelli, Leah; Kobryn, Simona; Tavarez, Isabella; Torres-Aragón, Alberto; Balderrama-Durbin, Christina M; Gibb, Brandon E; Charvet, Leigh E; Mattson, Richard E
The goal of this study was to clarify the contribution of prefrontal cortex activity to men's appraisals, affect states, and decision making in the context of hypothetical heterosexual dating scenarios lacking clear consent. Transcranial direct stimulation (tDCS) was applied to the prefrontal cortex to examine whether it would modify and reduce the likelihood of hypothetical dating violence. Participants (n = 102) responded to first-person vignettes wherein a woman responded either ambiguously or with a refusal to their sexual advance. While responding to the vignettes, participants received sham or active tDCS to modulate prefrontal cortex-mediated responding. Neuromodulation interacted with the communication response type of the woman in the vignette (e.g. ambiguous vs. refusal responses) to influence participants' reports of negative affect (F = 9.57, P = 0.002, Cohen's f2
PMCID:13225266
PMID: 42232253
ISSN: 2753-149x
CID: 6043932
Childhood adversity, allostatic load and epigenetic signatures in paediatric and adult-onset multiple sclerosis
O'Neill, Kimberly A; van der Veer, Bernard K; Charvet, Leigh; Azmy, Nadine; Friedman, Steven; Hu, Jiyuan; Lei, Kevin; Ortiz, Robin; Pehel, Shayna; Shi, Yidan; Sosa, Anna; Koh, Kian Peng; Maletic-Savatic, Mirjana; Krupp, Lauren B
Childhood adversity is increasingly recognized as a critical modifier of neurologic disorder development and disease severity, including in the neuroimmune disorder multiple sclerosis (MS). While previous studies have linked early-life adversity to increased MS susceptibility and more severe disease, the underlying biological mechanisms remain poorly understood. This study investigated associations between childhood adversity and MS clinical features, with a focus on two potential pathogenic mechanisms: allostatic load and epigenetic modifications. We evaluated 60 consecutively enrolled young adults with MS; 30 with paediatric-onset MS (POMS) and 30 with adult-onset MS (AOMS). At time of enrolment in this cross-sectional study, participants had MS disease duration of 6 years on average. POMS participants were mean 22.09 (2.66) years and AOMS participants were mean 32.41 (2.19) years old. 62% of participants were female. Childhood adversity was defined using a composite index of individual, family and socioeconomic measures captured by the adverse childhood experiences questionnaire, parental education level and estimated household income during childhood. Clinical outcomes included patient-reported SymptoMScreen questionnaire regarding MS symptom burden and MS neurologist-assessed disability using the Expanded Disability Status Scale (EDSS) of the participant's neurologic exam at the time of enrolment. Circulating biomarkers of allostatic load and genome-wide epigenetic profiles (DNA methylation via RRBS; reduced representation bisulfite sequencing) were also assessed. A history of high childhood adversity was associated with significantly greater patient-reported MS symptom burden (P = 0.001) and higher neurologist-reported EDSS disability scores (P = 0.028), independent of disease duration or timing of treatment initiation. There were no differences between childhood adversity and circulating biomarkers of allostatic load. While childhood adversity was not associated with global epigenetic changes across the entire cohort, stratified analysis revealed divergent methylation patterns by age of MS onset: POMS participants with childhood adversity had increased DNA methylation, whereas AOMS participants with childhood adversity showed decreased methylation compared to individuals without childhood adversity. None of the observed clinical and biologic differences were explained by differences in disease duration or the interval between symptom onset and treatment initiation. Our findings suggest that childhood adversity is associated with increased MS symptom burden and neurologic disability in young adults with MS. Childhood adversity may differentially shape the epigenome, depending on the age of MS onset, with potential implications for disease trajectory and therapeutic vulnerability. These results support the biological embedding of childhood adversity in MS and highlight the need for age- and exposure-sensitive approaches to understanding MS pathogenesis across the lifespan.
PMCID:12917236
PMID: 41728265
ISSN: 2632-1297
CID: 6009652
Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial
Knopman, David S; Koltai, Deborah; Laskowitz, Daniel; Becker, Jacqueline; Charvet, Leigh; Wisnivesky, Juan; Federman, Alex; Silverstein, Adam; Lokhnygina, Yuliya; Pilloni, Giuseppina; Haddad, Michelle; Mahncke, Henry; Van Vleet, Tom; Huang, Rong; Cox, Wendy; Terry, Diana; Karwowski, Jeannie; McCray, Netia; Lin, Jenny J; McComsey, Grace A; Singh, Upinder; Geng, Linda N; Chu, Helen Y; Reece, Rebecca; Moy, James; Arvanitakis, Zoe; Parthasarathy, Sairam; Patterson, Thomas F; Gupta, Aditi; Ostrosky-Zeichner, Luis; Parsonnet, Jeffrey; Kiriakopoulos, Elaine T; Fong, Tamara G; Mullington, Janet; Jolley, Sarah; Shah, Nirav S; Morimoto, Sarah Shizuko; Lee-Iannotti, Joyce K; Killgore, William D S; Dwyer, Brigid; Stringer, William; Isache, Carmen; Frontera, Jennifer A; Krishnan, Jerry A; O'Steen, Ashley; James, Melissa; Harper, Barrie L; Zimmerman, Kanecia O; ,
IMPORTANCE/UNASSIGNED:Treatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need. OBJECTIVE/UNASSIGNED:To test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:This was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID. INTERVENTIONS/UNASSIGNED:Participants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks. MAIN OUTCOMES AND MEASURES/UNASSIGNED:Cognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days. RESULTS/UNASSIGNED:A total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, -0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, -0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions. CONCLUSIONS AND RELEVANCE/UNASSIGNED:This phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT05965739.
PMCID:12603944
PMID: 41212544
ISSN: 2168-6157
CID: 5966502
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis
Abrams, Aaron W; Waltz, Michael; Casper, T Charles; Aaen, Gregory; Benson, Leslie A; Bernfeld, Eva-Chava M; Charvet, Leigh E; Chitnis, Tanuja; Francisco, Carla; Gorman, Mark P; Graves, Jennifer S; Krupp, Lauren; O'Neill, Kimberly; Lotze, Timothy E; Mar, Soe; Ness, Jayne; Rensel, Mary; Rodriguez, Moses; Rose, John; Rutatangwa, Alice; Schreiner, Teri; Shukla, Nikita; Tillema, Jan-Mendelt; Weinstock-Guttman, Bianca; Wheeler, Yolanda; Waubant, Emmanuelle; Krysko, Kristen M; ,
OBJECTIVE:To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. METHODS:Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. RESULTS:A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88). INTERPRETATION/CONCLUSIONS:Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.
PMID: 41195640
ISSN: 1531-8249
CID: 5960042
Automated thermo-mechanical therapy for immediate relief in chronic non-specific lower back pain: a randomized controlled trial
Donnery, Kyle; Pilloni, Giuseppina; FallahRad, Mohamad; Lee, Kiwon; Han, Byungyun; Park, Soonhi; Kim, Jihye; Charvet, Leigh; Bikson, Marom
OBJECTIVE/UNASSIGNED:Chronic non-specific lower back pain (cNSLBP) is a prevalent and disabling condition, imposing a substantial socioeconomic burden due to high healthcare costs and productivity losses, with limited accessible and effective long-term treatment options. Automated Thermo-mechanical Therapy (ATT) is a promising, non-drug intervention that leverages innovative technical advances to provide multimodal pain relief, offering accessibility and low-cost delivery. This study tested ATT for immediate pain relief in individuals with cNSLBP in a single-session, double-blind, randomized controlled trial. METHODS/UNASSIGNED:= 20) in a 40-min session with urn randomization. The active device applied heated cylindrical rollers along the spine, using far-infrared heat and mechanical tissue stimulation tailored to spinal alignment. In the control condition, the device used minimal mechanical therapy intensity without heat, targeting only the cervical area to avoid lower back therapeutic effects. Pre- and post-intervention assessments measured changes in pain intensity (primary outcome) via a 100-mm Visual Analog Scale for Pain (VAS-P100), alongside secondary outcomes assessing pain characteristics, anxiety, and functional mobility. RESULTS/UNASSIGNED:= 0.0031). No adverse events were reported, and all participants tolerated the intervention well. CONCLUSIONS/UNASSIGNED:A single session of ATT provides immediate, significant pain relief in individuals with cNSLBP, supporting its potential as a safe, non-invasive option for managing chronic back pain. Future studies should examine the long-term benefits of repeated ATT sessions and explore mechanistic insights into thermo-mechanical stimulation's effects on pain and function. CLINICAL TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov, identifier: NCT06769321.
PMCID:12827622
PMID: 41585325
ISSN: 2673-6195
CID: 6003002